Mirum Pharmaceuticals, Inc. (MIRM)
MIRM Stock Price Chart
Explore Mirum Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze MIRM price movements and trends.
MIRM Company Profile
Discover essential business fundamentals and corporate details for Mirum Pharmaceuticals, Inc. (MIRM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jul 2019
Employees
334.00
Website
https://www.mirumpharma.comCEO
Christopher Peetz
Description
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
MIRM Financial Timeline
Browse a chronological timeline of Mirum Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.73, while revenue estimate is $166.03m.
Earnings released on 6 May 2026
EPS came in at -$13.43 falling short of the estimated -$0.40 by -3.26k%, while revenue for the quarter reached $159.90m , beating expectations by +7.89%.
Earnings released on 25 Feb 2026
EPS came in at -$0.11 falling short of the estimated $0.02 by -650.00%, while revenue for the quarter reached $148.93m , beating expectations by +4.51%.
Earnings released on 4 Nov 2025
EPS came in at $0.05 surpassing the estimated -$0.10 by +150.00%, while revenue for the quarter reached $133.01m , missing expectations by -5.59%.
Earnings released on 6 Aug 2025
EPS came in at -$0.12 surpassing the estimated -$0.31 by +61.29%, while revenue for the quarter reached $127.79m , missing expectations by -1.79%.
Earnings released on 7 May 2025
EPS came in at -$0.30 surpassing the estimated -$0.39 by +23.08%, while revenue for the quarter reached $111.59m , beating expectations by +13.40%.
Earnings released on 26 Feb 2025
EPS came in at -$0.49 falling short of the estimated -$0.27 by -81.48%, while revenue for the quarter reached $99.41m , beating expectations by +2.87%.
Earnings released on 12 Nov 2024
EPS came in at -$0.30 surpassing the estimated -$0.45 by +33.33%, while revenue for the quarter reached $90.38m , missing expectations by -5.31%.
Earnings released on 7 Aug 2024
EPS came in at -$0.52 falling short of the estimated -$0.48 by -8.33%, while revenue for the quarter reached $77.88m , beating expectations by +3.49%.
Earnings released on 8 May 2024
EPS came in at -$0.54 falling short of the estimated -$0.40 by -35.00%, while revenue for the quarter reached $69.22m , missing expectations by -1.35%.
Earnings released on 28 Feb 2024
EPS came in at -$0.66 falling short of the estimated -$0.34 by -94.12%, while revenue for the quarter reached $69.55m , beating expectations by +2.65%.
Earnings released on 2 Nov 2023
EPS came in at -$0.57 surpassing the estimated -$0.64 by +10.94%, while revenue for the quarter reached $47.73m , missing expectations by -30.09%.
Earnings released on 3 Aug 2023
EPS came in at -$0.92 falling short of the estimated -$0.81 by -13.58%, while revenue for the quarter reached $37.50m , beating expectations by +15.48%.
Earnings released on 4 May 2023
EPS came in at -$0.80 surpassing the estimated -$0.96 by +16.67%, while revenue for the quarter reached $31.60m , beating expectations by +10.14%.
Earnings released on 8 Mar 2023
EPS came in at -$0.99 falling short of the estimated -$0.98 by -1.02%, while revenue for the quarter reached $27.91m , beating expectations by +13.58%.
Earnings released on 9 Nov 2022
EPS came in at -$1.02 surpassing the estimated -$1.05 by +2.86%, while revenue for the quarter reached $18.78m , missing expectations by -9.75%.
Earnings released on 4 Aug 2022
EPS came in at -$0.84 surpassing the estimated -$1.05 by +20.00%, while revenue for the quarter reached $17.48m , beating expectations by +13.41%.
Earnings released on 5 May 2022
EPS came in at -$1.17 surpassing the estimated -$1.39 by +15.83%, while revenue for the quarter reached $12.89m , beating expectations by +52.33%.
Earnings released on 9 Mar 2022
EPS came in at -$0.92 falling short of the estimated -$0.61 by -50.82%, while revenue for the quarter reached $3.14m , missing expectations by -94.99%.
Earnings released on 15 Nov 2021
EPS came in at -$1.55 surpassing the estimated -$1.63 by +4.91%, while revenue for the quarter reached $5.00m , beating expectations by +502.41%.
Earnings released on 5 Aug 2021
EPS came in at -$1.45 falling short of the estimated -$0.41 by -253.66%, while revenue for the quarter reached $11.00m , missing expectations by -24.14%.
MIRM Stock Performance
Access detailed MIRM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
